Complete remission of both immunoglobulin light chain amyloidosis and psoriasis after autologous hematopoietic stem cell transplantation: A case report
Immunoglobulin light chain amyloidosis (AL amyloidosis) is characterized by the deposition of abnormal amyloid protein produced by a pathological plasma cell clone in various organs and soft tissues. Hematopoietic stem cell transplantation (HSCT) is an effective way to treat AL amyloidosis. Psoriasi...
Gespeichert in:
Veröffentlicht in: | Medicine (Baltimore) 2018-12, Vol.97 (50), p.e13589-e13589 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | e13589 |
---|---|
container_issue | 50 |
container_start_page | e13589 |
container_title | Medicine (Baltimore) |
container_volume | 97 |
creator | Chen, Wencui Ren, Guisheng Zuo, Ke Huang, Xianghua |
description | Immunoglobulin light chain amyloidosis (AL amyloidosis) is characterized by the deposition of abnormal amyloid protein produced by a pathological plasma cell clone in various organs and soft tissues. Hematopoietic stem cell transplantation (HSCT) is an effective way to treat AL amyloidosis. Psoriasis is a common autoimmune disease (AID) and HSCT is a potential treatment for severe AIDs. We report a rare case of AL amyloidosis coincidence with psoriasis obtained continuous complete remission of the 2 diseases by autologous hematopoietic stem cell transplantation (ASCT).
A 58-year-old man with a 30-year history of psoriasis complaining of edema and hypotension for 2 weeks was referred to our institution. His urine protein was quantified 2.83 g/day, without hematuria and decrease of glomerular filtration rate.
Renal biopsy confirmed AL amyloidosis and multiple myeloma was excluded by bone marrow cytomorphologic examination.
Chemotherapy regimen based on bortezomib and thalidomide had achieved hematologic partial remission, but the kidney had no response and psoriasis was still active. Furthermore, he received a standard myeloablative conditioning with high dose melphalan followed by ASCT.
The erythema with slivery scales of psoriasis vulgaris gradually improved and almost disappeared after granulocyte implantation. He obtained persistent hematological complete remission, organ response and recovery of psoriasis.
We report a rare case of AL amyloidosis coincidence with psoriasis treated by ASCT. The outcome of this patient indicated that ASCT has therapeutic values both in AL amyloidosis and AIDs. |
doi_str_mv | 10.1097/MD.0000000000013589 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6320088</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>30558027</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3816-b0dd07d2e2098cc9c8e6d783b3f381710da122af290c59b1a9f0acd60408de0a3</originalsourceid><addsrcrecordid>eNpdUdtu1DAQtRAVXQpfgIT8A2nHdi42D0jVlhakVrzAczSxnY3BiSPbadUv4Xeb7UKB-sWemXMZ-RDyjsEpA9Wc3Vycwt_DRCXVC7JhlaiLStXlS7IB4FXRqKY8Jq9T-rEHNbx8RY4FVJUE3mzIr20YZ2-zpdGOLiUXJhp62oU8UDeOyxR2PnSLdxP1bjdkqgdc3zje--BMSC5RnAydU4gOH6s-20hxycGHXVgSHeyIOczB2ew0TdmOVFvvaY44pdnjlDGvrh_oOdWY9nvMIeY35KhHn-zb3_cJ-X756dv2c3H99erL9vy60EKyuujAGGgMtxyU1FppaWvTSNGJfp03DAwyzrHnCnSlOoaqB9SmhhKksYDihHw86M5LN1qj7bTu5ds5uhHjfRvQtf9PJje0u3Db1oIDSLkKiIOAjiGlaPsnLoN2n1N7c9E-z2llvf_X9onzJ5gVUB4Ad8GvH5p--uXOxnaw6PPwqFc1ihccmGSclVCsnboWDxR1o8E</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Complete remission of both immunoglobulin light chain amyloidosis and psoriasis after autologous hematopoietic stem cell transplantation: A case report</title><source>Wolters Kluwer Open Health</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>IngentaConnect Free/Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Chen, Wencui ; Ren, Guisheng ; Zuo, Ke ; Huang, Xianghua</creator><creatorcontrib>Chen, Wencui ; Ren, Guisheng ; Zuo, Ke ; Huang, Xianghua</creatorcontrib><description>Immunoglobulin light chain amyloidosis (AL amyloidosis) is characterized by the deposition of abnormal amyloid protein produced by a pathological plasma cell clone in various organs and soft tissues. Hematopoietic stem cell transplantation (HSCT) is an effective way to treat AL amyloidosis. Psoriasis is a common autoimmune disease (AID) and HSCT is a potential treatment for severe AIDs. We report a rare case of AL amyloidosis coincidence with psoriasis obtained continuous complete remission of the 2 diseases by autologous hematopoietic stem cell transplantation (ASCT).
A 58-year-old man with a 30-year history of psoriasis complaining of edema and hypotension for 2 weeks was referred to our institution. His urine protein was quantified 2.83 g/day, without hematuria and decrease of glomerular filtration rate.
Renal biopsy confirmed AL amyloidosis and multiple myeloma was excluded by bone marrow cytomorphologic examination.
Chemotherapy regimen based on bortezomib and thalidomide had achieved hematologic partial remission, but the kidney had no response and psoriasis was still active. Furthermore, he received a standard myeloablative conditioning with high dose melphalan followed by ASCT.
The erythema with slivery scales of psoriasis vulgaris gradually improved and almost disappeared after granulocyte implantation. He obtained persistent hematological complete remission, organ response and recovery of psoriasis.
We report a rare case of AL amyloidosis coincidence with psoriasis treated by ASCT. The outcome of this patient indicated that ASCT has therapeutic values both in AL amyloidosis and AIDs.</description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000013589</identifier><identifier>PMID: 30558027</identifier><language>eng</language><publisher>United States: the Author(s). Published by Wolters Kluwer Health, Inc</publisher><subject>Antineoplastic Agents - therapeutic use ; Bortezomib - therapeutic use ; Clinical Case Report ; Hematopoietic Stem Cell Transplantation - methods ; Hematopoietic Stem Cell Transplantation - standards ; Humans ; Immunoglobulin Light-chain Amyloidosis - complications ; Immunoglobulin Light-chain Amyloidosis - drug therapy ; Immunosuppressive Agents - therapeutic use ; Male ; Melphalan - therapeutic use ; Middle Aged ; Psoriasis - complications ; Psoriasis - drug therapy ; Thalidomide - therapeutic use ; Transplantation, Autologous - methods</subject><ispartof>Medicine (Baltimore), 2018-12, Vol.97 (50), p.e13589-e13589</ispartof><rights>the Author(s). Published by Wolters Kluwer Health, Inc.</rights><rights>Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3816-b0dd07d2e2098cc9c8e6d783b3f381710da122af290c59b1a9f0acd60408de0a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320088/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320088/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30558027$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Wencui</creatorcontrib><creatorcontrib>Ren, Guisheng</creatorcontrib><creatorcontrib>Zuo, Ke</creatorcontrib><creatorcontrib>Huang, Xianghua</creatorcontrib><title>Complete remission of both immunoglobulin light chain amyloidosis and psoriasis after autologous hematopoietic stem cell transplantation: A case report</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>Immunoglobulin light chain amyloidosis (AL amyloidosis) is characterized by the deposition of abnormal amyloid protein produced by a pathological plasma cell clone in various organs and soft tissues. Hematopoietic stem cell transplantation (HSCT) is an effective way to treat AL amyloidosis. Psoriasis is a common autoimmune disease (AID) and HSCT is a potential treatment for severe AIDs. We report a rare case of AL amyloidosis coincidence with psoriasis obtained continuous complete remission of the 2 diseases by autologous hematopoietic stem cell transplantation (ASCT).
A 58-year-old man with a 30-year history of psoriasis complaining of edema and hypotension for 2 weeks was referred to our institution. His urine protein was quantified 2.83 g/day, without hematuria and decrease of glomerular filtration rate.
Renal biopsy confirmed AL amyloidosis and multiple myeloma was excluded by bone marrow cytomorphologic examination.
Chemotherapy regimen based on bortezomib and thalidomide had achieved hematologic partial remission, but the kidney had no response and psoriasis was still active. Furthermore, he received a standard myeloablative conditioning with high dose melphalan followed by ASCT.
The erythema with slivery scales of psoriasis vulgaris gradually improved and almost disappeared after granulocyte implantation. He obtained persistent hematological complete remission, organ response and recovery of psoriasis.
We report a rare case of AL amyloidosis coincidence with psoriasis treated by ASCT. The outcome of this patient indicated that ASCT has therapeutic values both in AL amyloidosis and AIDs.</description><subject>Antineoplastic Agents - therapeutic use</subject><subject>Bortezomib - therapeutic use</subject><subject>Clinical Case Report</subject><subject>Hematopoietic Stem Cell Transplantation - methods</subject><subject>Hematopoietic Stem Cell Transplantation - standards</subject><subject>Humans</subject><subject>Immunoglobulin Light-chain Amyloidosis - complications</subject><subject>Immunoglobulin Light-chain Amyloidosis - drug therapy</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Male</subject><subject>Melphalan - therapeutic use</subject><subject>Middle Aged</subject><subject>Psoriasis - complications</subject><subject>Psoriasis - drug therapy</subject><subject>Thalidomide - therapeutic use</subject><subject>Transplantation, Autologous - methods</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdUdtu1DAQtRAVXQpfgIT8A2nHdi42D0jVlhakVrzAczSxnY3BiSPbadUv4Xeb7UKB-sWemXMZ-RDyjsEpA9Wc3Vycwt_DRCXVC7JhlaiLStXlS7IB4FXRqKY8Jq9T-rEHNbx8RY4FVJUE3mzIr20YZ2-zpdGOLiUXJhp62oU8UDeOyxR2PnSLdxP1bjdkqgdc3zje--BMSC5RnAydU4gOH6s-20hxycGHXVgSHeyIOczB2ew0TdmOVFvvaY44pdnjlDGvrh_oOdWY9nvMIeY35KhHn-zb3_cJ-X756dv2c3H99erL9vy60EKyuujAGGgMtxyU1FppaWvTSNGJfp03DAwyzrHnCnSlOoaqB9SmhhKksYDihHw86M5LN1qj7bTu5ds5uhHjfRvQtf9PJje0u3Db1oIDSLkKiIOAjiGlaPsnLoN2n1N7c9E-z2llvf_X9onzJ5gVUB4Ad8GvH5p--uXOxnaw6PPwqFc1ihccmGSclVCsnboWDxR1o8E</recordid><startdate>20181201</startdate><enddate>20181201</enddate><creator>Chen, Wencui</creator><creator>Ren, Guisheng</creator><creator>Zuo, Ke</creator><creator>Huang, Xianghua</creator><general>the Author(s). Published by Wolters Kluwer Health, Inc</general><general>Wolters Kluwer Health</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20181201</creationdate><title>Complete remission of both immunoglobulin light chain amyloidosis and psoriasis after autologous hematopoietic stem cell transplantation: A case report</title><author>Chen, Wencui ; Ren, Guisheng ; Zuo, Ke ; Huang, Xianghua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3816-b0dd07d2e2098cc9c8e6d783b3f381710da122af290c59b1a9f0acd60408de0a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Antineoplastic Agents - therapeutic use</topic><topic>Bortezomib - therapeutic use</topic><topic>Clinical Case Report</topic><topic>Hematopoietic Stem Cell Transplantation - methods</topic><topic>Hematopoietic Stem Cell Transplantation - standards</topic><topic>Humans</topic><topic>Immunoglobulin Light-chain Amyloidosis - complications</topic><topic>Immunoglobulin Light-chain Amyloidosis - drug therapy</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Male</topic><topic>Melphalan - therapeutic use</topic><topic>Middle Aged</topic><topic>Psoriasis - complications</topic><topic>Psoriasis - drug therapy</topic><topic>Thalidomide - therapeutic use</topic><topic>Transplantation, Autologous - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Wencui</creatorcontrib><creatorcontrib>Ren, Guisheng</creatorcontrib><creatorcontrib>Zuo, Ke</creatorcontrib><creatorcontrib>Huang, Xianghua</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Wencui</au><au>Ren, Guisheng</au><au>Zuo, Ke</au><au>Huang, Xianghua</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Complete remission of both immunoglobulin light chain amyloidosis and psoriasis after autologous hematopoietic stem cell transplantation: A case report</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2018-12-01</date><risdate>2018</risdate><volume>97</volume><issue>50</issue><spage>e13589</spage><epage>e13589</epage><pages>e13589-e13589</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>Immunoglobulin light chain amyloidosis (AL amyloidosis) is characterized by the deposition of abnormal amyloid protein produced by a pathological plasma cell clone in various organs and soft tissues. Hematopoietic stem cell transplantation (HSCT) is an effective way to treat AL amyloidosis. Psoriasis is a common autoimmune disease (AID) and HSCT is a potential treatment for severe AIDs. We report a rare case of AL amyloidosis coincidence with psoriasis obtained continuous complete remission of the 2 diseases by autologous hematopoietic stem cell transplantation (ASCT).
A 58-year-old man with a 30-year history of psoriasis complaining of edema and hypotension for 2 weeks was referred to our institution. His urine protein was quantified 2.83 g/day, without hematuria and decrease of glomerular filtration rate.
Renal biopsy confirmed AL amyloidosis and multiple myeloma was excluded by bone marrow cytomorphologic examination.
Chemotherapy regimen based on bortezomib and thalidomide had achieved hematologic partial remission, but the kidney had no response and psoriasis was still active. Furthermore, he received a standard myeloablative conditioning with high dose melphalan followed by ASCT.
The erythema with slivery scales of psoriasis vulgaris gradually improved and almost disappeared after granulocyte implantation. He obtained persistent hematological complete remission, organ response and recovery of psoriasis.
We report a rare case of AL amyloidosis coincidence with psoriasis treated by ASCT. The outcome of this patient indicated that ASCT has therapeutic values both in AL amyloidosis and AIDs.</abstract><cop>United States</cop><pub>the Author(s). Published by Wolters Kluwer Health, Inc</pub><pmid>30558027</pmid><doi>10.1097/MD.0000000000013589</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0025-7974 |
ispartof | Medicine (Baltimore), 2018-12, Vol.97 (50), p.e13589-e13589 |
issn | 0025-7974 1536-5964 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6320088 |
source | Wolters Kluwer Open Health; MEDLINE; DOAJ Directory of Open Access Journals; IngentaConnect Free/Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
subjects | Antineoplastic Agents - therapeutic use Bortezomib - therapeutic use Clinical Case Report Hematopoietic Stem Cell Transplantation - methods Hematopoietic Stem Cell Transplantation - standards Humans Immunoglobulin Light-chain Amyloidosis - complications Immunoglobulin Light-chain Amyloidosis - drug therapy Immunosuppressive Agents - therapeutic use Male Melphalan - therapeutic use Middle Aged Psoriasis - complications Psoriasis - drug therapy Thalidomide - therapeutic use Transplantation, Autologous - methods |
title | Complete remission of both immunoglobulin light chain amyloidosis and psoriasis after autologous hematopoietic stem cell transplantation: A case report |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T10%3A50%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Complete%20remission%20of%20both%20immunoglobulin%20light%20chain%20amyloidosis%20and%20psoriasis%20after%20autologous%20hematopoietic%20stem%20cell%20transplantation:%20A%20case%20report&rft.jtitle=Medicine%20(Baltimore)&rft.au=Chen,%20Wencui&rft.date=2018-12-01&rft.volume=97&rft.issue=50&rft.spage=e13589&rft.epage=e13589&rft.pages=e13589-e13589&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000013589&rft_dat=%3Cpubmed_cross%3E30558027%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/30558027&rfr_iscdi=true |